Synteract Thought Leaders to Address Industry Trends at Upcoming Conferences
RESEARCH TRIANGLE PARK, NC– August 29, 2019 – Synteract, an innovative contract research organization partnering with biotech and pharma companies to bring new medicines to market, will chair, present and exhibit at several key industry conferences this September. Synteract’s leaders will address current therapeutic, regulatory and industry trends and topics impacting clinical development today.
Attendees are invited to come meet with Synteract at any of these upcoming events:
- September 9 – 11: Orphan Drugs and Rare Diseases Global Congress 2019 Americas – Boston, MA – Derek Ansel, Director of Rare and Orphan Diseases at Synteract, will host a roundtable on “Patient-Centric Clinical Development: The importance of patient education for rare disease and advanced therapy trials”
- September 16 – 17: DIA/EFGCP Conference – Better Medicines for Children – Amsterdam – Dr. Martine Dehlinger-Kremer, Vice President, Pediatric Development Europe, will Chair Session 1: “Innovative approaches to pediatric development- State of play and possible impact”
- September 21 – 24: RAPS Regulatory Convergence – Philadelphia, PA –Lynne Marie Georgopoulos, RN, MSHS, RAC, Vice President, Pediatric Development Americas at Synteract, will present “Global Pediatric Drug Development Trivia” on Sept. 23 at 1:00 p.m.
- September 24 – 25: Outsourcing in Clinical Trials Southern California, booth #33 – San Diego, CA – Walter Boyle, Executive Director Biostatistics and Programming at Synteract, will present “Engagement and Analytics – the Simple Path to Value for your Data; or, how ‘Advanced’ do Analytics Really Need to Be?” on Sept. 25 at 10:00 a.m.
Email Kate.Mullis@synteract.com to meet with the Synteract team at any of these upcoming events.
For more information on Synteract’s upcoming conference schedule visit Synteract.com.
About Synteract
“Bringing Clinical Trials to Life” represents Synteract’s commitment to engage with drug developers, patients, investigators, and regulatory experts, to bring insights to action and make better therapies a reality. Synteract supports biotech and pharma companies across all phases of drug development to help bring new medicines to market. Synteract has conducted nearly 4,000 studies on six continents and in more than 60 countries. It has contributed to more than 240 product approvals. Synteract offers a notable depth of therapeutic expertise in oncology, dermatology, neuro degenerative, pediatrics, and rare and orphan diseases. Connect on LinkedIn and Twitter.
# # #
